Sustainable market access is rarely the result of a single submission or pricing decision. It reflects structured alignment across evidence, economics, reimbursement architecture and stakeholder behaviour.
The following anonymised case series reflect professional experience gained through prior senior advisory roles across UK, European, US and Australian healthcare systems.
Each example illustrates a systems-based approach to market access strategy.
A novel medical technology approaching European launch required clarity on reimbursement sequencing across priority markets. Regulatory planning was advanced, but payer strategy had not yet been structured.
The risk: regulatory approval without defined reimbursement pathways.
The core question was not “Will it be approved?”
It was “How will reimbursement decisions actually be made?”
A structured pre-launch access framework was developed:
Assessment of payer criteria, comparator relevance, budget sensitivities and pathway integration across target markets.
Refinement of clinical positioning to reflect payer-relevant endpoints rather than purely regulatory outcomes.
Alignment of economic modelling assumptions with anticipated HTA review frameworks.
Defined launch order based on reimbursement feasibility rather than regulatory timing alone.
This case illustrates the importance of pre-launch reimbursement architecture rather than reactive access planning.
(Experience reflects prior senior advisory role.)
A biotechnology product entering formal HTA review faced uncertainty around economic defensibility. Clinical data were robust, but alignment with payer decision thresholds was unclear.
The challenge was not evidence quantity — but evidence framing.
A structured realignment process was undertaken:
Adjusted assumptions to reflect payer-relevant pathway utilisation and realistic cost inputs.
Ensured clinical differentiation was articulated relative to actual standard of care.
Positioned ongoing data collection to reduce residual uncertainty.
Aligned economic narrative with anticipated HTA committee concerns.
The key shift was from technical modelling to strategic alignment with decision psychology.
A global MedTech portfolio required refinement of pricing corridors and reimbursement positioning across EU and US markets. Variability in coding and funding pathways was creating commercial inconsistency.
The strategic risk was price without pathway coherence.
Detailed analysis of funding routes, coding structures and tariff mechanisms across priority markets.
Defined global pricing parameters aligned with reimbursement feasibility and reference implications.
Considered regulatory and payer environment differences, including mature and emerging HTA systems.
Developed ongoing access optimisation structure to track uptake and funding evolution.
This case demonstrates that pricing is not purely commercial — it is structural.
(Case Series experience reflects prior senior Market Access & HEOR roles.)
Contact us to discuss your market access and reimbursement needs and explore tailored solutions for your products.
